

A New Test For ADHD

(NAPSA)—ADHD is the most commonly diagnosed behavioral disorder in children and is the fastest growing psychiatric disorder in adults.

Since 1990, the total number of children diagnosed with Attention Deficit Disorder has risen from 900,000 to 5.5 million and the use of the stimulant Ritalin has increased 700 percent. With no biological test to date, ADHD is currently diagnosed according to a set of psychiatric behavioral criteria, but this criteria is open to interpretation.



A new biological test for ADHD looks to offer more accurate diagnosis.

The lack of a clear-cut biological screening (test) for ADHD has sparked a vigorous public debate.

Fortunately, a biological diagnostic, Altropane, is currently being developed by Boston Life Sciences. This radio-imaging agent was recently found to be successful in identifying people who had already been diagnosed with ADHD. It is able to measure the levels of Dopamine Transporters in the brain which are significantly higher in people with ADHD.

“Trials have successfully demonstrated Altropane as an objective biological base to diagnose ADHD,” said Marc Lanser, MD, Chief Scientific Officer of Boston Life Sciences, developers of Altropane. “Our tests clearly indicate that there is a biochemical abnormality in individuals with symptoms of ADHD that Altropane can detect and measure.” This diagnostic is currently in clinical trials.